Back to results
US 9,000,027 B2Granted
Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, bcl-2 and caspase-3
AssigneeDana-Farber Cancer Institute, Inc.
InventorsA. Thomas Look, Samuel Sidi
Life of this patent
Estimating the term…
Abstract
The invention describes methods that are useful for treating cancer by administering a Chk1 inhibitor which can induce apoptosis in p53-defective cells when combined with a chemotherapy and/or radiotherapy. Methods for screening candidates for a Chk1 inhibitor-based cancer treatment regimen are also described.
Claims10
A method for determining whether a subject having a cancer is a candidate for a Chk1 inhibitor-based cancer treatment regimen, comprising:
- contacting cancer cells of the subject with a Chk1 inhibitor, in conjunction with a genotoxic stress, and then
- determining caspase-2 activation in the cancer cells,
- wherein if there is caspase-2 activation in the cancer cells, then the subject is identified as a candidate for a Chk1 inhibitor-based cancer treatment regimen.
Dependencies are inferred from the claim text.